Koustubh Ranade

Company: Immunocore

Job title: Head of Translational Medicine

Seminars:

Early Reduction in Circulating Tumor DNA, Regardless of RECIST Response, is Associated with Survival on Tebentafusp 10:30 am

• Circulating tumor DNA is emerging as an important marker of response to immunotherapies • Tebentafusp, a gp100-directed TCR-CD3 bispecific re-directs any T cell to kill gp100-expressing melanoma cells and has demonstrated survival benefit in metastatic uveal melanoma • Early reduction in circulating tumor, regardless of RECIST response, is associated with survival on tebentafusp  Read more

day: Day 2 - Morning